Micardis®. Observational Study in Patients With Essential Hypertension

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: High dose of Telmisartan, once daily; Drug: Low dose of Telmisartan, once daily

Study type: Observational

Funder types: Industry

Identifiers

NCT02200094

502.361

Details and patient eligibility

About

This study is designed to supplement, under conditions of usual clinical practice, the data on the efficacy and safety of Micardis® collected during the clinical studies.

Enrollment: 4,532 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of either sex over the age of 18 years suffering from essential hypertension requiring treatment according to the physician

Exclusion criteria

• Hypersensitivity to the active component or to any of the excipients
• Pregnancy and lactation
• Biliary obstructive disorders
• Severe hepatic impairment
• Severe renal impairment

Trial design

4,532 participants in 1 patient group

Outpatients with essential hypertension

Treatment:

Drug: Low dose of Telmisartan, once daily

Drug: High dose of Telmisartan, once daily